Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,047 | 4,315 | 1,918 | 1,729 | 4,264 |
| Receivables | 153 | 154 | 156 | 437 | 187 |
| TOTAL | $3,379 | $4,792 | $2,211 | $2,352 | $4,730 |
| Non-Current Assets | |||||
| PPE Net | 92 | 50 | 67 | 85 | 105 |
| Intangibles | 2,044 | 2,044 | 2,044 | 2,044 | 2,044 |
| Other Non-Current Assets | 657 | 698 | 737 | 788 | 839 |
| TOTAL | $2,793 | $2,792 | $2,848 | $2,917 | $2,988 |
| Total Assets | $6,172 | $7,584 | $5,059 | $5,269 | $7,718 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 958 | 1,319 | 1,275 | 1,721 | 2,752 |
| Accrued Expenses | 871 | 938 | 1,366 | 1,019 | 1,166 |
| Other current liabilities | 104 | 166 | 5,335 | 0 | 113 |
| TOTAL | $2,144 | $2,651 | $10,438 | $2,938 | $9,952 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 458 | 489 | 571 | 630 | 43,159 |
| TOTAL | $458 | $489 | $571 | $630 | $43,159 |
| Total Liabilities | $2,602 | $3,140 | $11,009 | $3,568 | $53,111 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 7,849 | 7,671 | 4,160 | 3,485 | 3,427 |
| Common Shares | 39 | 37 | 262 | 17 | 27 |
| Retained earnings | -244,126 | -242,885 | -239,738 | -231,536 | -225,769 |
| TOTAL | $3,570 | $4,444 | $-5,950 | $1,701 | $-45,393 |
| Total Liabilities And Equity | $6,172 | $7,584 | $5,059 | $5,269 | $7,718 |